StockData

Longeveron vs Pluri

LGVN and PLUR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LGVN and PLUR compare

Longeveron is the larger company, worth 5.6 times as much as Pluri ($67.3M against $12.1M).

Pluri grew revenue faster over the last twelve months (−24.0% versus −42.7% for Longeveron).

Longeveron keeps more of each dollar of sales as profit, with a net margin of −1978% compared with −2345% at Pluri.

Longeveron scores higher on the StockData Score (5 against 2 for Pluri), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLGVNPLUR
Size and price
Market cap$67.3M$12.1M
Share price$2.11$0.980
Change, 1 year−69.0%−74.6%
Change, 5 years−99.9%−95.4%
Beta (5Y)1.440.05
Employees3792
StockData Score
Total score5 (better)2
Valuation score00
Growth score01 (better)
Performance score01 (better)
Health score5 (better)0
Dividend score00
Valuation
P/S56.7×11.9× (better)
P/B6.5×–
FCF yield−30.5% (better)−167%
Growth
Revenue growth (TTM)−42.7%−24.0% (better)
Revenue growth, 5Y average−26.6%–
Profitability
Gross margin69.8% (better)44.6%
Operating margin−1993% (better)−2455%
Net margin−1978% (better)−2345%
FCF margin−1730% (better)−1990%
Return on equity−204%–
Return on invested capital−1412%–
Financial health
Debt / equity0.00–
Interest coverage–−26.8×
Current ratio2.63 (better)0.27
Altman Z-score−9.42 (better)−30.53
Piotroski F-score11
Dividends and buybacks
Buyback yield–−41.9%
Shareholder yield0.00% (better)−41.9%
Ownership
Held by institutions1.5%0.22%
Held by insiders43.8%54.6%
Insider net buying, 12 months–$1.3M
Short interest, % of float0.88%1.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.